RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX, FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today provides a corporate update.
20190315-HBP-Press-Release-Closes-Private-Placement-Extends-Warrants-Update.pdf